Cellebrite DI Ltd. (NASDAQ:CLBT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.70.

CLBT has been the topic of several recent research reports. DA Davidson reiterated a “buy” rating and set a $15.00 target price on shares of Cellebrite DI in a research report on Tuesday, September 15th. Weiss Ratings lowered shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. Needham & Company LLC cut their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research note on Friday, August 14th. JPMorgan Chase & Co. decreased their price objective on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Finally, Lake Street Capital lowered their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $10.93 on Friday. Cellebrite DI has a 52-week low of $9.58 and a 52-week high of $19.98. The firm has a market capitalization of $2.73 billion, a PE ratio of 49.68, a price-to-earnings-growth ratio of 1.70 and a beta of 1.15. The company’s fifty day moving average price is $12.59 and its two-hundred day moving average price is $13.37.

Insider Buying and Selling

In other Cellebrite DI news, CFO David Barter sold 41,734 shares of the stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total transaction of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at $5,474,507.22. This represents a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CMO David Gee sold 4,323 shares of Cellebrite DI stock in a transaction on Monday, August 24th. The shares were sold at an average price of $11.36, for a total value of $49,109.28. Following the transaction, the chief marketing officer directly owned 135,281 shares of the company’s stock, valued at approximately $1,536,792.16. The trade was a 3.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 329,658 shares of company stock worth $4,970,967 over the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Cellebrite DI

Several large investors have recently made changes to their positions in CLBT. Elevation Wealth Partners LLC acquired a new position in Cellebrite DI in the second quarter valued at about $44,000. PNC Financial Services Group Inc. increased its holdings in shares of Cellebrite DI by 59.6% during the first quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company’s stock worth $103,000 after buying an additional 2,785 shares in the last quarter. Pacer Advisors Inc. increased its holdings in shares of Cellebrite DI by 91.1% during the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock worth $105,000 after buying an additional 3,626 shares in the last quarter. Quantinno Capital Management LP bought a new position in shares of Cellebrite DI in the first quarter valued at approximately $150,000. Finally, ProShare Advisors LLC bought a new position in shares of Cellebrite DI in the fourth quarter valued at approximately $229,000. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. (NASDAQ: CLBT) develops digital intelligence and digital forensics solutions for law enforcement, public safety, government agencies and enterprises. Its technology helps authorized users access, collect, protect and analyze digital evidence from mobile devices, computers, cloud environments and other connected sources.

The company’s product portfolio includes UFED tools for mobile-device data collection, Inseyets for digital forensics investigations, and analytics and case-management solutions such as Pathfinder and Guardian.